Catalent is investing $130 million to add five additional Phase 3 through commercial-scale manufacturing suites to its gene therapy campus in Harmans, Maryland
The Catalent Gene Therapy campus in Harmans, near the Baltimore Washington International (BWI) airport, comprises two facilities that will house a total of 15 gene therapy suites, each designed to accommodate multiple bioreactors for commercial supply.
The first Harmans/BWI facility on the campus was recently approved by the FDA for commercial manufacturing and is expected to have all 10 cGMP suites qualified and operational by the first quarter of 2021. The five additional cGMP suites will be located in an adjacent building on the Harmans campus and are anticipated to be operational in the first half of 2022. The second Harmans building will also offer cold storage warehousing and additional office space.
“It is critical that we stay connected to the needs of our customers as they progress through the clinical pipeline. By increasing our late-stage manufacturing capacity at the Harmans campus, we will be able to meet demand through the medium term and take advantage of our shared resources, including the technical and manufacturing expertise that helped us reach the milestone of becoming an FDA-approved commercial partner,” commented Manja Boerman, Ph.D., President, Cell & Gene Therapy at Catalent.
Catalent’s Harmans/BWI commercial manufacturing campus is equipped with single-use manufacturing technology, and currently includes over 18,600 sqm of late-stage clinical and commercial-stage gene therapy production.
Upon outfitting of the second building, the large-scale Harmans/BWI production campus will encompass a total footprint of approximately 32,500 sqm. The campus is one of Catalent’s five gene therapy locations in Maryland and houses multiple cGMP manufacturing suites with pre-seed, bioreactor, and downstream rooms, together with fill/finish, testing, warehousing, supply chain, and central services capabilities.